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Resistance to anaplastic lymphoma kinase (ALK)-targeted therapy in ALK-positive non-small
cell lung cancer has been reported, with the majority of acquired resistance mechanisms
relying on bypass signaling. To proactively identify resistance mechanisms in ALK-positive
neuroblastoma (NB), we herein employ genome-wide CRISPR activation screens of NB cell
lines treated with brigatinib or ceritinib, identifying PIM1 as a putative resistance gene, whose
high expression is associated with high-risk disease and poor survival. Knockdown of PIM1
sensitizes cells of differing MYCN status to ALK inhibitors, and in patient-derived xenografts
of high-risk NB harboring ALK mutations, the combination of the ALK inhibitor ceritinib and
PIM1 inhibitor AZD1208 shows signiﬁcantly enhanced anti-tumor efﬁcacy relative to single
agents. These data conﬁrm that PIM1 overexpression decreases sensitivity to ALK inhibitors
in NB, and suggests that combined front-line inhibition of ALK and PIM1 is a viable strategy
for the treatment of ALK-positive NB independent of MYCN status.
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Deriving from precursor cells of the sympathetic nervoussystem, neuroblastoma (NB) is the most common anddeadly extracranial solid tumor in children1,2. NB pre-
sents at various sites along the sympathoadrenal axis, most
commonly in the adrenal medulla or paraspinal ganglia3. Char-
acterized by heterogeneous biological and clinical features ran-
ging from spontaneous regression to aggressive treatment-
resistant disease, NB is often referred to as a clinical enigma.
While low- and intermediate-risk forms of NB are highly curable,
over half of patients with high-risk disease suffer relapse and ﬁve-
year survival is 40–50%4. Therefore, novel treatment strategies
aimed at providing long-term disease remission are urgently
sought.
Large-scale genomic studies are bringing the genetic basis of
NB into focus, and there is evidence to suggest that high and low-
risk forms of the disease evolve through distinct genetic
mechanisms5. A study of 493 NB cases employing comparative
genomic hybridization showed hyperdiploidy involving whole-
chromosome gains to be associated with low-risk NB, while
segmental chromosome aberrations were associated with high-
risk NB6. Recent genome-wide sequencing analyses in large NB
patient cohorts have identiﬁed a relative paucity of recurrent
somatic mutations7–9.
Anaplastic lymphoma kinase (ALK) is the most commonly
mutated gene in NB, where gain-of-function mutations in the
kinase domain – namely at residues F1174, F1245, and R1275 –
are found in 8–10% of cases overall10,11. An additional 2–3% of
patients harbor focal ampliﬁcation of ALK, and this feature cor-
relates with poor survival10–12. Given the plethora of interest in
the development of ALK inhibitors in non-small cell lung cancer
(NSCLC), the assessment of these compounds in ALK-positive
NB quickly followed. Numerous recent studies have demon-
strated the efﬁcacy of ALK inhibitors against ALK-positive NB
cell lines and patient-derived xenografts13–15. Several of these
studies have documented the de novo resistance of the ALKF1174L
mutation to crizotinib and ceritinib, and have devised combina-
torial treatment strategies to enhance efﬁcacy13,16–19.
In patients with ALK-positive NSCLC, acquired resistance has
been shown to arise with ﬁrst, second and third-generation ALK
inhibitors, presenting a major challenge in the long-term use of
these compounds20. The most common mechanisms of resistance
to ALK inhibition in NSCLC are reported to involve bypass
signaling through functionally-related pathways, such that cells
grow in an ALK-independent manner when the kinase is inhib-
ited21. Bypass mechanisms include activation of EGFR22,
HER223, KRAS24, and IGF-1R25, and ampliﬁcation of KIT22.
To identify mechanisms of resistance to ALK inhibitors in
ALK-positive NB that involve bypass signaling, we conduct
genome-wide CRISPR activation (CRISPRa) screens26 in the NB
cell lines SH-SY5Y (ALKF1174L) and CHLA-20 (ALKR1275Q)
under treatment with brigatinib or ceritinib for 14 days. We
identify 25 putative resistance genes in SH-SY5Y, and successfully
validate 21 genes in vitro, and we further characterize PIM1 given
its association with high-risk disease and poor survival outcomes
in NB. Indeed, overexpression or knockdown of PIM1 induces
resistance or sensitization to ALK inhibitors, respectively, and
combinations of ALK inhibitors with AZD1208, a small-molecule
pan-PIM inhibitor, demonstrate at least additive effects if not
mild-to-moderate synergy in vitro. Moreover, in patient-derived
xenograft (PDX) models of high-risk NB harboring ALKF1245C or
ALKF1174L, the antitumor efﬁcacy of ceritinib and AZD1208 is
signiﬁcantly greater than either agent alone. Finally, over-
expression of PIM1 is similarly found to induce resistance to
brigatinib and ceritinib in cell lines derived from ALK-positive
anaplastic large cell lymphoma (ALCL). These data implicate
PIM1 in ALK inhibitor resistance in ALK-positive NB and other
ALK-driven malignancies, suggesting that combined pharmaco-
logical inhibition of ALK and PIM1 may be beneﬁcial in the
treatment of ALK-positive, high-risk NB.
Results
CRISPRa screens identify ALK inhibitor resistance genes. Prior
to CRISPRa screens, the NB cell lines SH-SY5Y (ALKF1174L) and
CHLA-20 (ALKR1275Q) were characterized for their sensitivity to
ALK tyrosine kinase inhibitors (TKIs) in order to determine the
ED50 and ED75 concentrations (Supplementary Table 1, Supple-
mentary Fig. 1a–c). Cells were then transduced with lentiviral
constructs to express the CRISPR-based synergistic activation
mediator (SAM) complex26. The functionality of the complex was
validated by transducing cells with gRNAs speciﬁc to 15 genes
previously shown to confer resistance to ALK inhibition in
NSCLC23. These data showed signiﬁcant overexpression of 6/15
and 8/15 genes in SH-SY5Y and CHLA-20 cell lines, respectively,
although a third of genes were not signiﬁcantly overexpressed in
either cell line (Supplementary Fig. 1d).
The SAM pooled gRNA library, targeting the transcription
start site of 23,430 RefSeq coding isoforms with three gRNA
sequences, was used for CRISPRa screening26. Cells were
transduced with the gRNA library before exposure to either
brigatinib or ceritinib. Genomic DNA was extracted from cells at
days 0 and 14, and deep-sequencing conducted to identify
enriched gRNAs (Fig. 1a). To further increase the stringency of
the analysis, we considered candidate genes to be those with
enriched gRNAs when exposed to both brigatinib or ceritinib at a
given concentration (i.e., ED50 or ED75) (Supplementary Data 1).
For SH-SY5Y cells, ALK TKI inhibitor treatment led to
signiﬁcant enrichment of gRNAs targeting 25 genes (p < 0.05,
unpaired Student’s t-test) (Fig. 1b). Interestingly, only three genes
(PIM1, MET and SAGE1) were signiﬁcantly enriched by both
inhibitors at ED50 and ED75 concentrations (Fig. 1b–d), suggest-
ing resistance mechanisms may be compound-speciﬁc and
concentration-dependent. Gene set enrichment analysis of
candidate resistance genes in SH-SY5Y cells in comparison with
hallmark and gene ontology gene sets in the Molecular Signatures
Database27 showed an enrichment for genes involved in negative
regulation of cell death (PIM1, BDNF, FAIM2, FOXP1, KRAS,
MET, and MYC) (Fig. 1e). This is consistent with their putative
roles in drug resistance and therefore conﬁrms the predictive
capability of this CRISPR gRNA fold-enrichment analysis
method. Data obtained from the SH-SY5Y cell line were
compared to those from the CRISPRa screen conducted in the
CHLA-20 cell line and revealed an overlap of 11 genes including
PIM1, MET, MYC, and KRAS (Fig. 1f, Supplementary Fig. 2,
Supplementary Data 2).
Functional validation of CRISPRa screen hits. Candidate genes
in SH-SY5Y and CHLA-20 cells were each functionally validated
by transducing cells with two enriched gRNAs individually and
by assessing their response to brigatinib or ceritinib. Of the
gRNAs targeting 25 different genes, 76% (38/50) induced a sig-
niﬁcant increase in the ED50 concentration for both brigatinib
and ceritinib in SH-SY5Y cells (p < 0.05, one-way ANOVA)
(Supplementary Fig. 3a, b; Supplementary Table 2), and 24 genes
were validated. Levels of gene overexpression were assessed for all
candidate genes by RT-qPCR (Supplementary Fig. 3c). Similar
data were obtained for the CHLA-20 cell line (Supplementary
Fig. 4). While overexpression levels achieved ranged from ~1.3 to
> 100,000-fold for both SH-SY5Y and CHLA-20 cell lines, the
ability of modest increases in gene expression to induce ALK
inhibitor resistance, such as those observed for BDNF, KRAS,
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MYC, and RRAS, supports the biological relevance of these results
(Supplementary Fig. 3c, Supplementary Fig. 4c).
PIM1 is a potential druggable target for ALK TKI-resistant
NB. To identify clinically-relevant genes from the CRISPRa
screens with the greatest potential to modify sensitivity to ALK
inhibitors, Kaplan–Meier overall and event-free survival analyses
were conducted for each gene (n= 24) based on its expression
level in primary ALK inhibitor-naive tumors from large NB
datasets (all risk groups) published by Zhang and colleagues28
and Kocak and colleagues29. High gene expression was associated
with signiﬁcantly worse overall survival (p < 0.01, Bonferroni-
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corrected, Log-rank test) and event-free survival (p < 0.05,
Bonferroni-corrected, Log-rank test) for 42% (10/24) and 46%
(11/24) of genes, respectively (Supplementary Table 3).
The potential for therapeutic targeting of each resistance gene
with FDA-approved drugs or compounds in clinical development
was then assessed using the Drug–Gene Interaction database30.
Five druggable genes were identiﬁed that may be amenable to
either direct targeting (PIM1, PIK3CD, and MET) or indirect
targeting (KRAS and MYC). MET was the top-ranking resistance
gene in the CRISPRa screens, enriched under brigatinib and
ceritinib treatments at both ED50 and ED75 concentrations (Fig. 1,
Supplementary Fig. 2). Activation of MET has previously been
shown to confer resistance to the ALK inhibitor alectinib in
NSCLC31, and resistance can be overcome with crizotinib, a
potent inhibitor of MET32. Given substantial evidence in the
literature that PIM1 mediates resistance to standard chemother-
apy33–35 as well as molecularly targeted agents36,37, that high
expression of PIM1 is a poor prognostic indicator in multiple
cancers38–40, and that recently Brunen et al.41. identiﬁed PIM
kinases as potential therapeutic targets in NF1 wild-type NB, this
gene was explored further.
In support of PIM1 as a prognostic biomarker, we found its
high expression to be signiﬁcantly associated with worse overall
survival (p < 0.001, Bonferroni-corrected, Log-rank test) in an
independent cohort of NB patients (n= 498) (Supplementary
Fig. 5a)28. Interestingly, PIM1 transcript level serves as a
prognostic biomarker independent of MYCN status in this cohort
(Supplementary Fig. 5b–e). However, as reported by Brunen
et al.41, we also found MYCN ampliﬁcation to be a stronger
predictor of poor prognosis than PIM1 (Supplementary Table 4).
Moreover, PIM1 expression is signiﬁcantly elevated in INSS stage
4 disease relative to earlier stages (p < 0.005, unpaired Student’s t-
test) and in patients with high-risk disease (p < 0.0001, unpaired
Student’s t-test) (Supplementary Fig. 5e, f)28.
PIM1 decreases sensitivity to ALK TKIs via apoptosis evasion.
SH-SY5Y and CHLA-20 cells were transduced with individual
PIM1- and non-targeting gRNAs, leading to 23- and 14-fold
increases in PIM1 mRNA, respectively (Fig. 2a), and then treated
with brigatinib or ceritinib for 72 h (Fig. 2b). Overexpression of
PIM1 induced signiﬁcant increases in both the brigatinib ED50
(p < 0.005, unpaired Student’s t-test) and ceritinib ED50 (p < 0.05,
unpaired Student’s t-test), thus conﬁrming decreased sensitivity
to ALK inhibition in these cell lines. Given that PIM1 has been
shown to induce drug resistance in other cancers by evading
apoptosis33,42,43, expression of apoptotic regulators and known
substrates downstream of PIM1 were investigated in SH-SY5Y
and CHLA-20 cells, following gRNA-induced overexpression of
PIM1. Speciﬁcally, expression of BAD44 and PRAS4045 was
analysed. An increase in p-BAD (Ser112), but not p-PRAS40, was
observed in SH-SY5Y and CHLA-20 cells overexpressing PIM1
(Fig. 2c) suggesting that in NB cells, PIM1 induces drug resistance
by evading apoptosis through direct phosphorylation of BAD. In
further evidence of a survival role for PIM1 in the context of ALK
inhibitor treatment, SH-SY5Y cells were treated with 1 µM bri-
gatinib or ceritinib for 48 h and a signiﬁcantly lower apoptotic cell
(annexin V+ /PI-) fraction was seen in inhibitor-treated cells
overexpressing PIM1 (p < 0.0001, unpaired Student’s t-test)
(Fig. 2d).
PIM1 decreases sensitivity to ALK TKIs in ALK-positive ALCL.
Given that a strong synergistic effect was previously shown on
simultaneous inhibition of ALK and PIM kinases in ALK-positive
ALCL cell lines46, PIM1 was overexpressed and sensitivity to ALK
inhibitors monitored in ALK-positive ALCL cell lines. Karpas 299
and SU-DHL-1 cells were transduced to express components of
the CRISPR SAM complex whose activity was conﬁrmed (Sup-
plementary Fig. 6a) before assessing their responses to brigatinib
or ceritinib upon overexpression of PIM1 as conducted previously
(Supplementary Fig. 6b, c). Indeed, overexpression of PIM1 led to
drug resistance, evidenced by signiﬁcant increases in the briga-
tinib ED50 (p < 0.01, unpaired Student’s t-test) and ceritinib ED50
(p < 0.001, unpaired Student’s t-test). Therefore, PIM1 is a
potential ALK inhibitor-resistance driver in ALCL and is worthy
of further exploration.
PIM inhibition alone is not efﬁcacious in NB cell lines. To
investigate the potential of PIM1 as a therapeutic target in ALK-
positive NB, transcript levels of PIM1 were assessed by RT-qPCR
across 25 NB cell lines that are diverse with respect to ALK and
MYCN status (Fig. 3a). As PIM can exist as one of 3 family
members (PIM1, PIM2, and PIM3) with many PIM inhibitors
showing overlapping activity, the transcript levels of all 3 proteins
was determined in the same 25 cell lines (Supplementary Fig. 7a).
For PIM1, expression levels varied across the cell lines and there
was no strong correlation between expression of the different
family members (Supplementary Fig. 7b). The activity of the pan-
PIM kinase inhibitor AZD1208, with greatest potency for PIM1,
was then determined in ALK-positive NB cell lines by 72-h
dose–response and 14-day colony formation assays (Fig. 3b, c).
Consistent with data reported by Brunen et al.41, cell lines were
relatively insensitive to AZD1208 at clinically relevant con-
centrations, with predicted ED50 values exceeding 10 µM in 8/8
NB cell lines expressing a range of ALK mutants (Fig. 3c). Similar
results were noted in response to treatment with PIMi, another
small-molecule pan-PIM kinase inhibitor in preclinical develop-
ment (Fig. 3c), suggesting that pharmacological inhibition of PIM
kinases alone is not a viable therapeutic strategy. The response of
ALK-negative NB cell lines to AZD1208 and PIMi was likewise
analyzed and a similar response was observed, indicating that the
Fig. 1 A genome-wide CRISPRa screen identiﬁes resistance genes in SH-SY5Y cells. a Experimental schema for genome-wide CRISPRa screening in NB
cells. Cell lines were transduced with lentiviral vectors to confer stable expression of dCas9-VP64 and MS2-p65-HSF1 before transduction with a lentiviral
library of guide RNA (gRNA) sequences (3 gRNAs per coding isoform). Transduced cells were selected and then exposed to DMSO (vehicle) or ALK
inhibitors for 14 days, after which genomic DNA was extracted and gRNA sequences were PCR-ampliﬁed and subjected to Illumina HiSeq sequencing.
b Venn diagram of candidate genes from CRISPRa screen with brigatinib or ceritinib at ED50 and ED75 concentrations in SH-SY5Y cells. c Log-normalized
read counts for each gRNA in untreated (DMSO) vs ALK TKI-treated SH-SY5Y cell populations. Dashed black lines represent linear regressions. Data
represent the average of two biological replicates. Genes common to both brigatinib and ceritinib treatments are shown (MET, PIM1, SAGE1). d gRNAs
ranked by fold-change vs difference in log-normalized read counts between DMSO and ALK TKI-treated SH-SY5Y populations. Only gene hits common to
brigatinib and ceritinib treatments are shown (MET, PIM1 and SAGE1). e Top ﬁve gene sets by gene set enrichment analysis including all validated genes
(n= 25) identiﬁed by the CRISPRa screen in SH-SY5Y cells treated with brigatinib or ceritinib. Validated genes were compared with hallmark and GO gene
sets in MSigDB (FDR < 0.0001). Blue shading indicates an enriched gene set. f Pie chart to show the overlap in candidate resistance genes detected by the
CRISPRa screens in both SH-SY5Y and CHLA-20 cells.
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Fig. 2 PIM1 inhibits apoptosis through phosphorylation of BAD. a Expression of PIM1 in SH-SY5Y or CHLA-20 cells transduced with non-targeting (NT) or
PIM1-targeting gRNA molecules, by RT-qPCR and immunoblot. RT-qPCR data were normalized to cells treated with non-targeting gRNA and show means ±
s.d. of triplicate experiments. b 72-h dose–response assays of brigatinib or ceritinib-exposed SH-SY5Y or CHLA-20 cells transduced with NT or PIM1-
targeting gRNA. Data points represent means ± s.d. of triplicate experiments. ED50 values were compared by an unpaired Student’s t-test. c Immunoblot of
known PIM1 targets and apoptotic mediators in SH-SY5Y and CHLA-20 cells transduced with NT- or PIM1-targeting gRNA, the latter leading to PIM1
overexpression. Data are representative of three independent experiments. Numbers below the blot represent the densitometric measurement of pBAD
levels normalized to BAD. d Percentage of apoptotic (annexin V+ /PI-) PIM1-overexpressing SH-SY5Y cells after 48-h of treatment with 1 µM brigatinib or
ceritinib. Data points in the bar chart show means ± s.d. of triplicate experiments. p-values were calculated using an unpaired Student’s t-test. Source data
for this ﬁgure are provided as a Source Data ﬁle.
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response to PIM inhibitors is independent of ALK status (Sup-
plementary Fig. 7c).
PIM1 is a therapeutic target in combination with ALK. In order
to determine whether inhibition of PIM1 may enhance the efﬁ-
cacy of ALK inhibitors in ALK-positive NB, CHLA-20 (MYCN-
WT) and KELLY (MYCN-ampliﬁed) cells were transduced with a
PIM1-targeting shRNA, achieving an approximate 50% reduction
in PIM1 expression as conﬁrmed by RT-qPCR (Fig. 3d, e). PIM1
knockdown increased the sensitivity of cells to brigatinib and
ceritinib, indicated by a signiﬁcant decrease in ED50 concentra-
tions after 72-h of treatment (p < 0.0005, unpaired Student’s
t-test, Fig. 3g) (Fig. 3f, g).
Recent human dose-escalation studies have displayed general
tolerability for the PIM inhibitor AZD120847, which prompted
the assessment of combined ALK and PIM1 inhibition in this
study. To this end, cell viability following 72-h exposure to
AZD1208 in combination with brigatinib or ceritinib in SH-
SY5Y, CHLA-20 and KELLY cells using dose–response matrices
in log-scale format was analyzed. The drug interactions were
characterized using the Bliss Independence model described
elsewhere48. A wide range of combination index (CI) values were
determined across the concentration ranges for all cell lines and
both ALK inhibitors, but for the most part CI values were <1,
indicative of mild synergy between ALK and PIM inhibition
(Fig. 4a). These ﬁndings were extended to other ALK-positive NB
cell lines by assessing cell viability after treatment with ﬁxed
concentrations of brigatinib and AZD1208 (Fig. 4b). CI values
ranged from 0.59 to 0.95, indicating variable levels of synergy
between cell lines. The cellular consequences of drug interaction
were then determined by analysis of apoptosis in several cell lines
treated with brigatinib or AZD1208, alone and in combination. In
3/4 cell lines tested, synergy was observed between the drugs
(with an additive effect observed in the fourth cell line tested) in
terms of the apoptotic cell fraction detected after 48-h treatment
(Fig. 4c).
Combined inhibition of ALK and PIM in ALK-positive PDX.
To assess the efﬁcacy of combined ALK and PIM inhibition
in vivo, the COG-N-426 × (ALKF1245C; MYCN-WT) and COG-
N-453 × (ALKF1174L; MYCN-ampliﬁed) PDX models of high-risk
NB were employed. COG-N-426x is derived from the same pri-
mary patient tumor as the COG-N-426 cell line, although COG-
N-426x cells were directly grafted from human to mouse without
intermediary in vitro culture. As ceritinib is currently undergoing
phase I assessment in patients with ALK-positive pediatric
malignancies including NB (NCT02780128; NCT01742286), this
ALK TKI was selected for in vivo investigation.
NOD scid gamma mice were treated daily with either vehicle
(0.5% hydropropyl methylcellulose; 0.5% Tween-80), single-agent
ceritinib (30 mg/kg), single-agent AZD1208 (15 mg/kg) or both
agents in combination (Supplementary Fig. 8a). In the COG-N-
426x model, single-agent treatment with ceritinib or AZD1208
led to a delay in tumor growth relative to vehicle treatment,
although not signiﬁcantly different from one another (Fig. 5a).
However, the combination of ceritinib and AZD1208 led to a
signiﬁcant reduction in tumor volume at day 14 relative to either
agent alone (p < 0.05, Mann–Whitney test). Kaplan–Meier
survival analysis showed a signiﬁcant increase in event-free
survival (EFS) for animals treated with the combination of
ceritinib and AZD1208 (median EFS= 29.5 days) relative to
single-agent ceritinib (median EFS= 19 days; p < 0.01, Log-rank
test) or AZD1208 (median EFS= 15 days; p < 0.01, Log-rank test,
Fig. 5b), where an event was deﬁned as a tumor reaching 15 mm
in any direction. All compounds were well-tolerated, with no
signiﬁcant decrease in body weight or lethal toxicity observed
(Fig. 5c).
Residual COG-N-426x tumors harvested at the experimental
end-point recapitulated histological features of NB, with H&E
staining showing small, round, monomorphic cells with nuclear
hyperchromasia and scant cytoplasm (Supplementary Fig. 8b).
Consistent with the superior efﬁcacy of combination treatment,
tumor immunostaining showed a signiﬁcant reduction in cell
proliferation as indicated by positivity for Ki67 (Supplementary
Fig. 8c; p < 0.001, unpaired Student’s t-test) in combination-
treated tumors versus single-agent ceritinib-treated tumors.
The superior efﬁcacy of the combination therapy was
conﬁrmed in a second cohort of mice bearing MYCN+ COG-
N-453x NB xenografts (Fig. 5d, e). Tumor volume was
signiﬁcantly reduced at day 8 in combination-treated mice
relative to mice treated with single-agent ceritinib or AZD1208
(p < 0.05, Log-rank test) (Fig. 5d). Kaplan–Meier survival analysis
showed a signiﬁcant increase in event-free survival (EFS) for
COG-N-453x mice treated with the combination (median EFS=
31.5 days) relative to single-agent ceritinib (median EFS= 9 days;
p < 0.05, Log-rank test) or AZD1208 (median EFS= 18 days; p <
0.05, Log-rank test) (Fig. 5e). These observations conﬁrm the
efﬁcacy and tolerability of combined ALK and PIM1 inhibition in
xenograft models of high-risk, ALK-positive NB independent of
MYCN status.
PIM1 is upregulated by ALK inhibition in PDX. Analysis of
PIM1 mRNA expression in residual COG-N-426x tumors at the
experimental end-point by RT-qPCR showed a signiﬁcant
increase in PIM1 expression in ceritinib-treated animals relative
to animals treated with AZD1208 or vehicle (DMSO) (p < 0.05,
unpaired Student’s t-test), while the combination of AZD1208
and ceritinib showed levels of PIM1 comparable to those in
vehicle-treated animals (Fig. 5f). This is in agreement with a gene
expression dataset previously reported by Lambertz et al.49
showing that in ALK-positive NB cell lines treated with 0.32 µM
of the preclinical ALK inhibitor NVP-TAE684 for 6 h, PIM1 is
signiﬁcantly upregulated relative to vehicle-treated cells in 4/5 cell
lines tested (Supplementary Fig. 8d). In addition, the magnitude
of gene upregulation appears to be independent of endogenous
PIM1 expression levels (Supplementary Fig. 8e).
Discussion
The majority of patients undergoing treatment with molecularly
targeted anti-cancer compounds acquire resistance after an initial
response. For example, therapeutic resistance to ALK inhibitors is
well documented for ALK-positive NSCLC and is known to arise
through both ALK-dependent and -independent mechanisms20.
ALK inhibitors are undergoing clinical assessment for ALK-
positive pediatric malignancies including NB50,51, and growing
evidence from preclinical studies indicates that both de novo and
acquired resistance will be of concern13,16–19. In this study, we
proactively investigated mechanisms of resistance to ALK inhi-
bitors using CRISPRa screens in NB cell lines harboring recurrent
point mutations in the ALK tyrosine kinase domain, including
those previously shown to confer endogenous resistance to the
ALK inhibitor crizotinib.
Importantly, a genome-wide CRISPRa screening approach
allowed us to fully explore all potential resistance mechanisms in
an unbiased manner. Our work has expanded on the ﬁndings of
previously published studies investigating ALK inhibitor resis-
tance mechanisms in NB13,52; AXL activation was identiﬁed by a
phospho-proteomic assay in NB cell lines rendered resistant to
ALK inhibitors through continuous exposure to increasing con-
centrations of drugs52, whereas MYCN overexpression was
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reported as a resistance mechanism in another study13. Of note,
whilst MYC was identiﬁed as a resistance driver in our screen,
neither MYCN nor AXL were among the resistance driver can-
didates identiﬁed. This may be due to insufﬁcient overexpression
of MYCN or AXL induced by the CRISPR-SAM system as
variable overexpression levels were observed for different genes in
our study. Ultimately, the in vitro studies conducted to date are
potentially predictive of resistance mechanisms in patients, but
until more children with NB have been treated with ALK inhi-
bitors and biopsy material is taken for study at relapse, CRISPR
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screens, while having their caveats, offer the best approach for
global, unbiased identiﬁcation of resistance mechanisms. CRIS-
PRa screens were conducted, employing the second-generation
ALK inhibitors brigatinib and ceritinib at both ED50 and ED75
concentrations to enable discrimination between potential com-
pound- and concentration-dependent resistance mechanisms. As
expected, we observed the greatest number of resistance genes at
the higher (ED75) concentrations of brigatinib and ceritinib in
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SH-SY5Y and CHLA-20 cells. Distinct sets of resistance genes
were observed amongst different concentrations of ALK inhibi-
tors, with only three genes (MET, PIM1, and SAGE1) common to
both inhibitors at both ED50 and ED75 concentrations. Activation
of c-MET has previously been shown to confer resistance to
alectinib in ALK-positive NSCLC31, consistent with a partial
functional redundancy of c-MET and ALK due to convergence on
several pro-survival signaling pathways20. PIM1 is a serine/
threonine kinase, the expression of which is controlled by the
JAK/STAT pathway, and has also been associated with resistance
to chemotherapy33–35 and molecularly targeted agents36,37 in
several cancer types, but to our knowledge not previously for NB.
Of the 16 resistance genes identiﬁed in brigatinib and ceritinib-
treated NB cells at the ED75, two are known to be activated
downstream of ALK, namely KRAS and PIK3CD (PI3Kδ). Copy
number gain and mutational activation of KRAS at codon 12 has
been shown to confer resistance to crizotinib and ceritinib in
ALK-positive NSCLC24,53. Similarly, mutational activation of
PIK3CA is reported as a resistance mechanism to alectinib and
ceritinib in these patients54,55. Interestingly, we identiﬁed a
resistance gene (MFSD2A)56 encoding a sodium-dependent
transporter of fatty acids expressed in brain endothelium, in
both SH-SY5Y and CHLA-20 cells treated with brigatinib or
ceritinib at ED75 concentrations, most likely functioning as an
efﬂux pump for ALK inhibitors although this remains to be
investigated further. Encouragingly, gene set enrichment analysis
of the putative resistance genes showed an enrichment for genes
involved in negative regulation of cell death.
MET was the only putative resistant gene common to all ALK
inhibitors. Given that crizotinib is a potent inhibitor of c-MET31
and can overcome ALK inhibitor resistance driven by activation
of MET in NSCLC32, we chose to focus instead on PIM1 whereby
high PIM1 gene expression levels were found to be associated
with advanced, high-risk disease and poor survival outcomes on
analysis of published datasets28,29. In addition to validating PIM1
as a resistance gene in NB cell lines, we sought to determine
whether PIM1 induces resistance to ALK inhibition in another
ALK-driven pediatric cancer, namely ALCL, since full-length
ALK and NPM-ALK have been shown to activate common
downstream pathways such as Ras/MAPK, PI3K/AKT and JAK/
STAT50. Indeed, overexpression of PIM1 in ALK-positive ALCL
cell lines decreased sensitivity to brigatinib and ceritinib, con-
sistent with results published previously demonstrating robust
synergy between a small-molecule pan-PIM inhibitor and crizo-
tinib in ALCL cell lines40. Therefore, further studies investigating
the potential for combined PIM and ALK inhibition in other
ALK-positive malignancies are warranted.
We assessed the in vitro responses of both ALK-positive and
ALK-negative NB cells to several small-molecule pan-PIM kinase
inhibitors and found that cells were relatively insensitive after 72
h of exposure. However, knockdown of PIM1 by RNA inter-
ference sensitized cells to ALK inhibition and the combination of
ALK inhibitors with AZD1208 demonstrated mild synergy,
prompting us to investigate the combination of ceritinib and
AZD1208 in vivo. To examine the clinical relevance of this drug
combination, we employed two patient-derived models of high-
risk NB harboring ALKF1245C or ALKF1174L mutations respec-
tively. PDX models are perhaps more representative of the clinical
scenario than are cell lines due to their relative genetic likeness to
tumors in patients, as opposed to long-term cultured cell lines
that have evolved further from the original malignancy. We
observed a signiﬁcant delay in tumor growth with the combina-
tion treatment relative to single-agent treatments in both models.
Of note, PIM inhibition sensitized both MYCN-ampliﬁed and
wild-type, ALK-driven neuroblastoma cells to ALK inhibitors
both in vitro and in vivo, suggesting co-inhibition of PIM and
ALK as a viable strategy to enhance the efﬁcacy of ALK inhibitors.
It has previously been shown that ALK and MYCN are part of a
positive feedback loop whereby ALK regulates expression of
MYCN through repression of HPB157. However, our data, par-
ticularly the in vivo PDX data suggest that combined PIM and
ALK inhibition is effective independent of MYCN status. More-
over, PIM1 mRNA levels were signiﬁcantly elevated in COG-N-
426x tumors treated with ceritinib relative to vehicle at the
experimental end-point, thus providing in vivo evidence of PIM1
as a resistance gene. In summary, our data conﬁrm that PIM1
induces resistance to ALK inhibitors in NB cell lines and also
demonstrate the potential for combined pharmacological inhibi-
tion of ALK and PIM1 in patients with ALK-positive, high-
risk NB.
Methods
Cell lines and cell culture. The neuroblastoma cell lines CHLA-15, CHLA-20,
CHLA-42, CHLA-90, CHLA-95, CHLA-171, COG-N-426 (Felix), LA-N-5, LA-N-
6, NB-1643, NB-EBC1, SK-N-BE(1), SK-N-BE(2), SK-N-FI, SMS-KAN, SMS-KCR,
and SMS-LHN were obtained from COG. CHP-134, IMR-32, KELLY, LA-N-1 and
SH-SY5Y were obtained from the European Collection of Authenticated Cell
Cultures (ECACC). GI-ME-N, NBL-S and NGP were obtained from German
Collection of Microorganisms and Cell Cultures (DSMZ) and 293FT was obtained
from Thermo Fisher Scientiﬁc. CHLA-15, CHLA-20, CHLA-42, CHLA-90, CHLA-
95, CHLA-171, COG-N-426 (Felix), NB-1643, NB-EBC1 and NBL-S cells were
cultured in IMDM (Gibco, Cat#21980032) supplemented with 20% FBS, 1%
insulin-transferrin-selenium (ITS; Gibco, Cat#41400045) and 1% penicillin/strep-
tomycin (PS). CHP-134, GI-ME-N, IMR-32, KELLY, LA-N-1, LA-N-5, LA-N-6,
NGP, SK-N-BE(1), SK-N-BE(2), SK-N-FI, SMS-KAN, SMS-KCNR, and SMS-LHN
cells were cultured in RPMI 1640 medium (Gibco, Cat#21875091) supplemented
with 10% FBS, 1% insulin-transferrin-selenium (ITS) and 1% penicillin/strepto-
mycin (PS). SH-SY5Y and 293FT cells were cultured in DMEM (Gibco,
Cat#41966029) supplemented with 10% FBS and 1% PS. Cells were grown at 37 °C
in a humidiﬁed incubator with 5% CO2. All cells were mycoplasma-free and
subjected to quarterly in-house testing using the EZ-PCR Mycoplasma Detection
Kit (Geneﬂow, Cat#K1-0210).
Genotyping of cell lines for ALK status. Total RNA was extracted using the
RNeasy Plus Mini Kit (Qiagen, Cat#74134). RNA was reverse transcribed using
iScript Reverse Transcription Supermix (Bio-Rad, Cat#1708840). The kinase
domain of ALK was PCR-ampliﬁed from 10 ng cDNA using the Q5 High-Fidelity
PCR Kit (NEB) with primers F: CGGCATCATGATTGTGTACC; R:
GTTGCTTTTGCTGGGGTATG. Amplicons were resolved by agarose gel elec-
trophoresis and extracted using the QIAquick Gel Extraction Kit (Qiagen,
Cat#28706). DNA was Sanger sequenced with a custom sequencing primer, F:
ACCTCGACCATCATG. Chromatograms were analysed in SnapGene Viewer
using that of CHP-134 as reference, since its ALK coding sequence is identical to
RefSeq NM_004304 (NCBI-BLAST).
Cell viability assays. Cells were seeded in black/clear bottom 96-well plates
(Greiner Bio-One, Cat#655209) at densities that resulted in near-conﬂuency after
96 h. After 24 h, the media was aspirated and 200 µL fresh media was added
containing compounds in log-scale concentrations (0, 1, 3, 10, 30, 100, 300, 1000,
3000 nM) in technical triplicate. DMSO concentration was ﬁxed at 0.3% for all
cells. Plates were sealed with AeraSeal breathable ﬁlm (Excel Scientiﬁc, Cat#BS-25)
to reduce evaporation and cells were incubated at 37 °C. After 68 h, 120 µL
CellTiter-Blue cell viability reagent (Promega, Cat#G8082) diluted 1:5 with media
was added to each well and cells were incubated at 37 °C for 4 h. After 4 h,
ﬂuorescence was read on a SpectraMax i3 microplate reader (Molecular Devices).
PBS was used to calculate background signal for subtraction from all measure-
ments. Normalized dose–response curves were generated by non-linear regression
and ED50 values calculated with GraphPad Prism 7 software (GraphPad
Software Inc).
Colony formation assays. Cells were seeded into six-well plates at 103 cells per
well. After 24 h, compounds were added at the following log-scale concentrations:
0, 30, 100, 300, 1000, 3000 nM (0.3% DMSO) and media was replaced every three
days. Cells were cultured for 12 days, after which each colony in the DMSO control
comprised at least 50 cells. Colonies were ﬁxed with 10% neutral buffered formalin,
stained with 0.05% (w/v) crystal violet (25% methanol), washed and imaged on an
ImageQuant LAS-4000 imaging system (GE Life Sciences).
Synergy experiments. For dose–response curves, cells were treated with log-scale
concentrations of ALK inhibitors as described above in addition to ﬁxed con-
centrations of AZD1208 as indicated. Potential synergy between ALK inhibitors
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and AZD1208 was evaluated by calculating the combination index (CI) based on
the Bliss Independence model48. The CI can be calculated with the following
equation: CI= (Ea+ Eb−((Ea*Eb))/Eab, where Ea indicates the viability effect of
drug A (ALK inhibitor) and Eb indicates the viability effect of drug B (AZD1208)
and Eab indicates the viability effect of the drug combination. CI < 1 indicates
synergism, CI= 1 indicates additivity and CI > 1 indicates antagonism. For
dose–response matrices, cells were treated with log-scale concentrations of each
compound in 8 × 8 grids and DMSO concentration was maintained at 0.3%. Cell
viability was measured with CellTiter-Blue as described above and data were
normalized to the average of the untreated well. All synergy experiments were
performed in technical triplicate.
Cloning of guide sequences. Promoter-targeting guide sequences for the 15 genes
used to conﬁrm CRISPR SAM activity were designed with the Cas9 Activator Tool
(sam.genome-engineering.org/database) and the oligonucleotides are shown in
Supplementary Table 5. Guide sequences for targeting of the screen candidate
genes were obtained from the Addgene depositor datasheet (www.addgene.org/
pooled-library/zhang-human-sam-v1) and modiﬁed by the addition of BsmBI
recognition sites (Supplementary Table 6). Oligonucleotide sequences for genera-
tion of 20 bp non-targeting (scrambled) guide sequence were kindly shared by Dr
Feng Zhang. Double-stranded sequences were generated by phosphorylating and
annealing oligonucleotides with T4 polynucleotide kinase (NEB, Cat#M0201) and
T4 DNA ligase (NEB, Cat#M0202), respectively. Guide sequences were cloned into
the lenti sgRNA(MS2)_zeo backbone (Addgene, Cat#61427) by Golden Gate
assembly using BsmBI (NEB, Cat#R0580) and ampliﬁed in NEB Stable competent
E. coli. A full protocol is available at www.sam.genome-engineering.org/protocols.
Production of lentivirus and cell transduction. Low-passage 293FT cells were
cultured in DMEM with 5% FBS. Cells were seeded at 40% conﬂuency in six-well
plates for small-scale production or 15 cm dishes for larger scale production. Once
conﬂuency reached 80–90%, cells were transfected with pMD2.G (Addgene,
Cat#12259), psPAX2 (Addgene, Cat#12260) and transfer plasmid at equimolar
ratios using TransIT-293 transfection reagent (Mirus Bio, Cat#MIR2704) according
to the manufacturer’s instructions. The media containing lentivirus was collected
after 60 h. Cellular debris was removed by centrifugation at 500 × g and the media
was passed through a 0.45 µm polyethersulfone (PES) ﬁlter. The supernatant was
stored at −80 °C. To generate stable cell lines, cells were seeded into culture vessels
in media supplemented with 5% FBS, grown to near-conﬂuency and then trans-
duced with lentiviral media. After 20 h, cells were split into media containing
antibiotics as follows: 10 µg/mL blasticidin for 7 days, 300 µg/mL hygromycin for
7 days, 500 µg/mL zeocin for 5 days or 1.5 µg/mL puromycin for 5 days. Antibiotic
concentrations were determined by kill curve analysis.
Generation of CRISPR SAM cell lines. CHLA-20 and SH-SY5Y cells were co-
transduced with lentiviruses carrying the dCas9-VP64_blast (Addgene, Cat#61425)
and lenti MS2-p65-HSF1_hygro (Addgene, Cat#61426) constructs at MOI~0.2 and
selected as described above. To conﬁrm CRISPR SAM activity, cells were trans-
duced with lentivirus carrying the lenti sgRNA(MS2)_zeo construct (Addgene,
Cat#61427) into which guide sequences were cloned and overexpression of the
target genes was conﬁrmed by RT-qPCR.
RT-qPCR analysis. Total RNA was isolated from cell lines using the RNeasy Plus
Mini Kit (Qiagen, Cat#74134). In total, 1 µg RNA was reverse transcribed using
iScript Reverse Transcription Supermix (Bio-Rad, Cat#1708840) and 20 ng cDNA
template was used for qPCR. cDNA was ampliﬁed with PowerUp SYBR Green
Master Mix (Thermo Fisher Scientiﬁc, Cat#A25918) and 600 nM primers on a
QuantStudio 6 Flex Real-Time PCR System (Thermo Fisher Scientiﬁc) under
standard cycling conditions. Relative quantiﬁcation (ΔΔCT) analysis was conducted
with normalization to GAPDH. All reactions were performed in technical tripli-
cates and each plate included no-RT and no-template controls. Primer sequences
for all RT-qPCR experiments are listed in Supplementary Table 7.
CRISPR SAM screens. The zeocin-resistant pooled gRNA library v1 (Addgene,
Cat#1000000057) was packaged into lentivirus in 15 cm plates, as described above.
CHLA-20 and SH-SY5Y cells stably expressing dCas9-VP64 and MS2-p65-HSF1
were seeded into 15 cm plates and transduced with the lentiviral gRNA library at
MOI 0.3–0.4, with a minimum representation of 500 transduced cells per guide.
After 20 h, cells were split into 500 µg/mL zeocin for 5 days and passaged every
second day, maintaining >500 cells per guide. After 5 days of selection, 3.6 × 107
cells were harvested as a day 0 sample. The remaining cells were split into duplicate
populations and cultured in the presence of vehicle (0.3% DMSO), brigatinib or
ceritinib at ED50- and ED75-equivalent concentrations as determined by 72-h
dose–response assay. Cells were maintained below 80% conﬂuency and harvested
after 14 days of treatment for genomic DNA extraction.
Preparation of HiSeq libraries. Genomic DNA was extracted with the QIAamp
DNA Blood Maxi Kit (Qiagen, Cat#51194). The gRNA regions were PCR-ampliﬁed
for 22 cycles with Herculase II Fusion DNA Polymerase (Agilent, Cat#600677) in
23 replicate reactions, with a total input of 230 µg DNA corresponding to 500X
library coverage. Each 100 µL reaction comprised Herculase II reaction buffer
(2 mM Mg2+), 1 mM dNTPs, 2% DMSO, 250 nM pooled forward primer, 250 nM
speciﬁc reverse primer and 10 µg template DNA. The Illumina-compatible primers
contained P5/P7 adapters, a staggered region (forward primers only) and 8 bp
index barcodes (Supplementary Table 8). PCR products were pooled and 400 µL
was ethanol precipitated, resuspended in 100 µL water and resolved on a 3%
agarose gel at 100 V for 5 h. The 270–280 bp amplicon was isolated with the
QIAquick Gel Extraction Kit (Qiagen, Cat#28706) according to the manufacturer’s
protocol, except the QC buffer was incubated at room temperature. Products were
tested for concentration and speciﬁcity using High sensitivity D1000 ScreenTape
and qPCR using KAPA Library Quantiﬁcation Kit, multiplexed, spiked with PhiX
Control v3 library (Illumina, Cat#FC-110-3001) and run on an Illumina HiSeq
2500 on Rapid Run 1 × 100 bp mode for 115 cycles.
NGS gene enrichment analysis. Raw FASTQ ﬁles were downloaded from the
Bauer Core server using FileZilla. Initial QC was conducted with FastQC (Babra-
ham Bioinformatics, Cambridge, UK) to assess the general quality of the sequence
runs. Raw FASTQ sequencing ﬁles were demultiplexed with bcl2fastq2 v2.2, then
matched to the guide sequences from the library ﬁles using the MAGeCK count
function. Due to the absence of non-targeting guides in this library, an analysis to
control for the empirical false positive rate could not be performed. Read counts
per gRNA were calculated by averaging gRNA read counts of two biological
replicates per screen condition and normalizing to total gRNA read count. Nor-
malized read counts in ALK inhibitor-treated cell populations were log-
transformed and compared with those in DMSO-treated cell populations to
identify gRNAs that were preferentially enriched under ALK inhibitor conditions.
An arbitrary threshold of >1.5-fold enrichment was applied and genes with mul-
tiple gRNAs exceeding this threshold were considered to be enriched. To improve
stringency, only genes enriched in both brigatinib and ceritinib screens at a given
concentration (ED50 or ED75) were considered as candidates.
Gene set enrichment analysis. Hallmark and gene ontology gene expression
datasets were downloaded from the molecular Signatures database (MSigDB)
v6.227 and analyzed with GSEA v3.0 (www.broadinstitute.org/gsea)58,59. Enrich-
ment was carried out by calculating overlaps between MSigDB datasets and
putative resistance genes in SH-SY5Y cells treated with brigatinib and ceritinib at
ED50 and/or ED75 concentrations.
Analysis of public datasets. All candidate genes identiﬁed from the CRISPR SAM
screens were investigated by Kaplan–Meier event-free survival analysis with
microarray data from primary neuroblastoma patient cohorts using R2: Genomics
Analysis and Visualization Platform (http://r2.amc.nl). The following cohorts were
analysed: Kocak (n= 476) [accession: GSE45547]29 and SEQC (n= 498) [acces-
sion: GSE49710]28. The cut-off method was selected as scan to determine the
optimal threshold for each gene, and signiﬁcance was assessed by log-rank test. The
p-values were corrected for multiple testing using the Bonferroni method. The
hazard ratio was determined through a Cox proportional hazards model using the
coxph function in the survival package in R. The data analyzed in Supplementary
Figs. 8d and e can be accessed through ArrayExpress (accession number E-MTAB-
3205)49.
Immunoblot analysis. Adherent cells were washed and lysates prepared with pre-
chilled RIPA Lysis and Extraction Buffer (Thermo Fisher Scientiﬁc, Cat#89900)
supplemented with 1% Halt Protease and Phosphatase Inhibitor Cocktail (Thermo
Fisher Scientiﬁc, Cat#78440). Around 50 µg protein lysate per sample was resolved
by SDS-PAGE and transferred to a 0.45 µm PVDF membrane for 2.5 h at 80 V
according to the manufacturer’s protocol (Bio-Rad). The membrane was blocked in
5% BSA and blotted with antibodies overnight at 4 °C. Primary antibodies were as
follows and diluted 1:1000 unless speciﬁed otherwise: anti-BAD (CST, Cat#9292),
anti-phospho-BAD (Ser112) (CST, Cat#9291), anti-BAX (CST, Cat#5023), anti-
BCL-2 (CST, Cat#4223), anti-PIM1 (CST, Cat#2907), anti-PRAS40 (CST,
Cat#2691), anti-phospho-PRAS40 (Thr246) (CST, Cat#13175), anti-AKT (CST,
Cat#9272), anti-pAKT (CST, Cat#9271), anti-ALK (CST, Cat#3633), anti-pALK
(CST, Cat#3341), anti-GAPDH (CST, Cat#97166; diluted 1:10,000), and anti-α-
tubulin (CST, Cat#T9026; diluted 1:10,000). Membranes were then incubated with
secondary antibodies for 1 h at room temperature. Secondary antibodies were as
follows and diluted 1:10,000: anti-mouse HRP-immunoglobulins (Dako,
Cat#P0260) and anti-rabbit HRP-immunoglobulins (Dako, Cat#P0448). If
required, membranes were stripped once with stripping buffer (2% SDS, 62.5 mM
Tris HCl [pH 6.8], 0.8% β-mercaptoethanol) and re-blocked. Membranes were
developed with Immobilon Western Chemiluminescent HRP Substrate (Merck
Millipore) and imaged with an ImageQuant LAS-4000 imaging system (GE Life
Sciences). Raw, unprocessed blots are presented for Fig. 2c in the Source Data ﬁle.
Mice and animal housing. NOD scid gamma (NSG) mice were obtained from
Charles River and housed in groups of 2–5. Animal work was carried out under UK
Home Ofﬁce licence P4DBEFF63 according to the Animals (Scientiﬁc Procedures)
Act 1986, and was approved by the University of Cambridge Animal Welfare and
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-13315-x ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:5428 | https://doi.org/10.1038/s41467-019-13315-x | www.nature.com/naturecommunications 11
Ethical Review Body (AWERB). We have complied with all relevant ethical reg-
ulations for animal testing and research in the UK.
Xenograft study. COG-N-426x and COG-N-453x patient-derived xenograft
(PDX) cells were obtained from the Childhood Cancer Repository maintained by
the Children’s Oncology Group (COG). Cells were suspended in Matrigel diluted
1:2 with PBS and 3 × 105 cells (300 µL) injected into the left ﬂank of NSG mice at 6-
8 weeks of age. Tumors were measured daily with manual calipers and tumor
volumes estimated using the modiﬁed ellipsoid formula: V= ab2/2, where a and b
(a > b) are length and width measurements. Once tumors reached approximately
75 mm3, mice were randomly allocated into four treatment groups (n= 4 per
group) and treated daily with the following agents by oral gavage at 10 µL per gram
body weight: vehicle (0.5% hydroxypropyl methylcellulose; 0.5% Tween-80), cer-
itinib (30 mg/kg), AZD1208 (15 mg/kg) or the combination of ceritinib (30 mg/kg)
and AZD1208 (15 mg/kg). Mice were euthanized once tumors reached 15 mm in
any direction (deﬁned as an event for event-free survival analysis) and tumors were
ﬁxed in 10% neutral-buffered formalin for 24 h. Tumors were parafﬁn-embedded
and 10 µm sections were cut from central regions. COG-N-426x tissue sections
were stained with hematoxylin and eosin or with antibodies against ALK (CST,
Cat#3633) or Ki-67 (CST, Cat#12202). All antibodies were diluted 1:200 and
incubated on slides overnight at 4 °C. Slides were then incubated with secondary
biotinylated antibody (Vector Laboratories, Cat#BA-1000) in 2% goat serum for 30
min at room temperature. Slides were washed and incubated with VECTASTAIN
Elite ABC reagent (Vector Laboratories, Cat#PK-6101) for 45 min followed by
incubation with Vector DAB HRP substrate (Vector Laboratories, Cat#SK-4100)
until the desired stain intensity was achieved. Slides were counterstained with
Mayer’s hemalum solution (Carl Roth, Cat#T865.1) and mounted with Aquatex
reagent (Sigma-Aldrich, Cat#1085620050). RNA was extracted from 10 µm sec-
tions of COG-N-426x tumors using the PureLink FFPE RNA Isolation Kit and
treated with RQ1 RNase-Free DNase before reverse transcription and qPCR as
described earlier. In total 20 ng cDNA was used per qPCR reaction.
Analysis of apoptosis. Cells were collected by centrifugation, washed once in PBS,
then resuspended in 100 μL Annexin V Binding Buffer containing 5 μL/reaction
APC-Annexin V (BioLegend, Cat#640920) and incubated for 30 min at room
temperature. APC-Annexin V was then removed from the cells following cen-
trifugation, washed once in Annexin V Binding Buffer (Thermo Fisher Scientiﬁc,
Cat#V13246), and cells resuspended in 100 μL Annexin V Binding Buffer con-
taining 1 mg/mL propidium iodide (Sigma-Aldrich, Cat#P4170-10MG). Data were
acquired using a BD Accuri C6 ﬂow cytometer and analyzed using FlowJo
V10 software. Cells were gated according to physical parameters in order to discard
cell debris (FCS/SSC) and cell clumps (width/area).
Statistical analysis. Methods for statistical analysis are speciﬁed in the relevant
Fig. captions. All Student’s t-tests, ANOVA models, correlation analyses and
Kaplan–Meier survival analyses in mice were conducted with GraphPad Prism
7 software. Heat maps for cell viability were produced in Excel 2016. Gene set
enrichment analysis was conducted in GSEA v3.0 software as described above.
Kaplan–Meier survival analyses in human patients from published gene expression
datasets were generated in R2: Genomics Platform as described above.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All relevant data supporting the key ﬁndings of the study are available within the article
and its Supplementary Information ﬁles or from the corresponding author upon
reasonable request. The source data underlying Figs. 2, 3a, 3c–g, 4 and 5, and
Supplementary Figs. 1a, d, 3, 4, 5a–d, 5f–g, 6, 7 and 8c-e are provided as a Source Data
ﬁle. A reporting summary for this Article is available as a Supplementary Information
ﬁle. Publicly available microarray data used for Kaplan-Meier event-free survival analysis
is available from the NCBI gene expression omnibus with accession codes: GSE4554729
and GSE4971028. The data analyzed in Supplementary Figs 8d and e can be accessed
through ArrayExpress with accession code E-MTAB-320549.
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